Study: 9/11 toxic exposure driving up dementia rates
By GREGORY ZELLER // A new Stony Brook University study of responders to the Sept. 11, 2001, terrorist attacks adds to mounting evidence of the harmful long-term effects of Ground…
NIH National Institute on Aging
SBU: After 22 years, 9/11 heroes still paying the price
By GREGORY ZELLER // Twenty-two years later, 9/11 continues to exact a cruel toll: Stony Brook University scientists are tracking early-onset cognitive declines in first responders. This week’s memorials and…
Researchers eye Alzheimer’s link in 9/11 responders
By GREGORY ZELLER // Biomarkers similar to those found in the brains of Alzheimer’s patients are appearing in the brains of first responders to the 9/11 terrorist attacks, and Stony…
‘Dormant’ biotech wakes on Alzheimer’s fast track
By GREGORY ZELLER // A pre-clinical-stage biopharmaceutical company is being fast-tracked toward a potential Alzheimer’s treatment, after taking a decidedly slow road. Stony Brook-based Avanti Biosciences Inc. actually launched in…
ALZ: Genetic variants can run, but they can’t hide
The Feinstein Institute for Medical Research is targeting genetic risk factors behind Alzheimer’s disease, the first of many steps toward new potential treatments. Feinstein Institute assistant professor Yun Freudenberg-Hua has…